The effects of a short course of antibiotics on alvimopan and metabolite pharmacokinetics

Journal of Clinical Pharmacology

Volumn 50, Issue 3, 2010, Pages 338-349

  Schmith, Virginia D ^a   Johnson, Brendan M ^a   Vasist, Lakshmi S ^a   Kelleher, Dennis L ^a   Hewens, Deborah A ^a   Young, Malcolm A ^a   Ameen, Vanessa ^a   Dukes, George E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Alvimopan; Antibiotics; Drug interaction; Modeling and simulation

Indexed keywords

ALVIMOPAN; CIPROFLOXACIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; MALE; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RASH; SIMULATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; RECEPTORS, OPIOID, MU; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 77649212123     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009347474     Document Type: Article

References (20)

1. Viscusi ER, Goldstein S., Witkowski T., et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study [erratum in: Surg Endosc. 2006;20:537]. Surg Endosc. 2006 ; 20: 64-70. (Pubitemid 43097035)
2. Delaney CP, Weese JL, Hyman NH, et al. Alvimopan Postoperative Ileus Study Group. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005 ; 48: 1114-1125 ; discussion 1125-1126 ; author reply 1127-1129.
3. Wolff BG, Michelassi F., Gerkin TM, et al. Alvimopan Postoperative Ileus Study Group. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004 ; 240: 728-734 ; discussion 734-735.
4. Webster L., Jansen JP, Peppin J., et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized
5. double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008 ;137: 428-440.
6. Foss JF, Schmith VD, Wallin BA, Du W., Melikian A., Hillerud A. Alvimopan (Entereg), a novel opioid antagonist achieves active systemic concentrations. Clin Pharmacol Ther. 2005 ; 77: P74.
7. Foss J., Fisher DM, Schmith VD Pharmacokinetics of alvimopan and its metabolite in healthy subjects and patients in postoperative ileus trials. Clin Pharmacol Ther. 2008 ; 83: 770-776.
8. Schmith VD, Garnett W., Barr WH, et al. Alvimopan pharmacokinetics (PK) & pharmacodynamics (PD) in patients with chronic constipation. Clin Pharmacol Ther. 2005 ; 77: P49.
9. Walk ST, Young VB Emerging insights into antibiotic-associated diarrhea and Clostridium difficile infection through the lens of microbial ecology. Interdiscip Perspect Infect Dis. 2008 ; 125081: 1-7.
10. Cavet ME, West M., Simmons NL Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 1997 ; 121: 1567-1578. (Pubitemid 27343382)
11. Lowes S., Simmons NL Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 ; 135: 1263-1275.
12. Bartlett JG, Condon RE, Gorbach SL, Clarke JS, Nichols RL, Ochi S. Veterans Administration cooperative study on bowel preparations for elective colorectal operations: impact of oral antibiotic regimen on colonic flora, wound irrigations cultures, and bacteriology of septic complications. Ann Surg. 1978 ; 188: 249-254.
13. Van den Bogaard Aejm, Weidema WF, van Boven CPA, Van der Waay D. Recolonization and colonization resistance of the large bowel after three methods of preoperative preparation of the gastrointestinal tract for elective colorectal surgery. J Hyg Comb. 1986 ; 97: 49-59.
14. Brumfitt W., Franklin I., Grady D., Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to healthy subjects. Antimicrob Agents Chemo. 1984 ; 26: 757-761.
15. Holt HA, Lewis DA, White LO, Bastable SY, Reeves DS Effect of oral ciprofloxacin on the faecal flora of healthy subjects. Eur J Clin Microbiol Inf Dis. 1986 ; 5: 201-205.
16. Zhou SF, Xue CC, Yu XQ, Li C., Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 ; 29: 687-710.
17. Shakeri-Nejad K., Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother. 2006 ; 7: 639-651.
18. Beattie DT, Cheruvu M., Mai N., et al. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmaco. 2007 ; 375: 205-220.
19. Smart K., Churchill A., Boyle G., Schmith VD Investigation of the CNS penetration of alvimopan and its active metabolite in mdr1a/b (-/-) knockout and control mice. AAPS J. 2007 ; 9 (suppl 2). 2081.
20. Julious SA Tutorial in biostatistics: sample sizes for clinical trials with normal data. Stat Med. 2004 ; 23: 1921-1986.